A black box warning lawsuit is a legal claim against a pharmaceutical manufacturer for injuries caused by a medication that carries the FDA’s most serious safety warning—a “black box warning.” These lawsuits allege that manufacturers failed to adequately warn patients and healthcare providers about serious or life-threatening risks, or that they failed to implement proper safety measures during the time the drug carried this warning classification. Black box warnings are the strongest cautionary label the FDA can require, placed on medications with evidence of serious adverse events, and their presence on a drug’s label creates significant legal liability for the manufacturer. For example, in March 2020, the FDA added a black box warning to Singulair (montelukast), a common asthma and allergy medication, after discovering links to serious neuropsychiatric events including depression, suicidal behavior, and anxiety. This single warning triggered hundreds of lawsuits, with 247 cases consolidated in New Jersey’s multicounty litigation (MCL 637) by March 2022, demonstrating how a black box warning can transform a widely used medication into the subject of mass tort litigation.
Black box warning lawsuits represent one of the most serious categories of pharmaceutical injury claims because the FDA has already determined that the drug poses known, significant risks. Unlike cases where plaintiffs must prove a hidden danger, black box warning litigants argue that the manufacturer knew or should have known about the serious harm and either failed to warn adequately or didn’t take sufficient precautions to prevent injury. These cases often involve medications that were prescribed to hundreds of thousands or millions of patients before the black box warning was added, meaning that many people took the drug while unaware of its serious dangers. The legal landscape for black box warning claims continues to evolve, particularly as the FDA reassesses older warnings and manufacturers face mounting evidence of harm.
Table of Contents
- What Is a Black Box Warning and Why Do These Lawsuits Arise?
- The Singulair Neuropsychiatric Litigation and Ongoing Cases
- Other Medications with Active Black Box Warning Lawsuits
- How Manufacturers Face Legal Liability for Black Box Warnings
- Recent FDA Changes and Their Impact on Black Box Warning Lawsuits
- What to Do If You Believe You’ve Been Harmed by a Black Box Warning Medication
- The Future of Black Box Warning Litigation
- Conclusion
- Frequently Asked Questions
What Is a Black Box Warning and Why Do These Lawsuits Arise?
A black box warning is the FDA’s strongest safety alert for prescription medications. It appears as a black box bordered in black on the drug‘s label and package insert, making it visually distinct from other warnings. The black box warning indicates that a medication has evidence of serious or life-threatening adverse events. The FDA only requires a black box warning when there is substantial evidence that the drug poses a significant risk of serious harm, such as organ damage, severe psychological effects, fatal outcomes, or other grave consequences. The FDA added approximately 10 to 15 new black box warnings annually in recent years, and currently there are dozens of medications on the market carrying this designation, ranging from antipsychotics to chemotherapy drugs to biologics. Lawsuits arise from black box warnings because these labels create a legal acknowledgment of known danger. When a manufacturer places a black box warning on a drug, it essentially admits that the medication poses a serious, known risk.
Plaintiffs’ lawyers argue that if the FDA determined the risk was serious enough to warrant the strongest warning, then patients who were harmed before or during the black box warning period should have been protected from that harm. Legal liability exists on two primary theories: first, that the manufacturer failed to adequately warn healthcare providers and patients about the dangers before the black box warning was added, and second, that the manufacturer failed to take sufficient precautions to prevent harm even after the warning was required. For comparison, medications with standard warnings typically face fewer lawsuits because the FDA has not deemed the risk as severe enough to warrant the strongest alert. The Singulair litigation exemplifies how a black box warning can trigger mass tort litigation. Before March 2020, Singulair was widely prescribed to millions of patients for asthma and allergies without a black box warning, despite reports of neuropsychiatric effects. When the FDA added the black box warning in 2020, it confirmed that montelukast carried a risk of serious psychiatric problems including depression, suicidal thoughts, agitation, and mood changes. This revelation prompted lawsuits from patients who claim they or their family members experienced these effects while taking Singulair. The consolidated litigation in New Jersey demonstrates the scale: 247 cases were consolidated in MCL 637 by March 2022, and these cases remain in the state system rather than being consolidated in federal court, which is a relatively unusual procedural arrangement for a major pharmaceutical lawsuit.
The Singulair Neuropsychiatric Litigation and Ongoing Cases
The Singulair black box warning litigation centers on serious neuropsychiatric adverse effects that the FDA determined warranted the drug’s strongest safety label. The neuropsychiatric events documented in the black box warning include depression, suicidal thoughts and behavior, anxiety, agitation, sleep disturbances, mood swings, and other psychiatric symptoms. What makes these cases particularly significant is that many patients taking Singulair were not warned about these psychiatric risks—the medication is commonly prescribed to children and adolescents for asthma and allergies, and psychiatric injuries in young people can be especially severe and life-altering. Plaintiffs in the consolidated New Jersey litigation claim that Singulair caused serious psychiatric harm, including suicidal ideation, suicide attempts, or completed suicides in some cases, and that these injuries were preventable had patients and their physicians been adequately informed of the risks. As of 2026, the Singulair cases remain in the New Jersey multicounty litigation system (MCL 637) rather than being consolidated in a federal multidistrict litigation (MDL). This procedural posture is notable because most large-scale pharmaceutical injury cases are eventually consolidated in federal court, which allows for more coordinated discovery and streamlined litigation.
The fact that Singulair cases have remained in state court suggests ongoing negotiations about potential settlement, changes in case management, or different procedural preferences among the parties. The 247 cases consolidated by March 2022 represent only a portion of the total number of potential claimants, as the statute of limitations allows patients to file claims years after the black box warning is added. A significant limitation of the Singulair litigation is the challenge of proving causation—that is, proving that Singulair specifically caused the psychiatric injury and not some other factor such as the underlying asthma or allergies, concurrent mental health conditions, or other medications. Defense arguments typically emphasize that asthma itself can trigger anxiety and stress, and that psychiatric conditions are multifactorial. Plaintiffs must typically present medical evidence linking their psychiatric symptoms to Singulair use, often including medical records, pharmacy records, and expert testimony from psychiatrists or neuropsychiatrists. This causation burden makes Singulair cases more complex than black box warning cases involving medications where the link to injury is more direct or objective.
Other Medications with Active Black Box Warning Lawsuits
Beyond Singulair, numerous other medications with FDA black box warnings have generated active litigation. Suboxone, a medication used to treat opioid addiction, has faced lawsuits related to a black box warning regarding the risk of overdose death and medication interactions. Ozempic, the widely prescribed diabetes and weight-loss medication, has been subject to various litigation claims, though not all relate to black box warnings specifically. Other medications with pending lawsuits include psychiatric drugs, cancer therapies, and biologics—any medication category where the FDA has determined that serious, documented adverse events warrant a black box warning. The common thread across these different black box warning lawsuits is that the FDA has already made a formal determination that the medication poses a serious known risk.
This means that manufacturers have a difficult task defending these cases, as they must explain why they didn’t adequately protect patients from a risk that the FDA later deemed serious enough to require the strongest warning. In many cases, manufacturers may have known about the risks for years before the black box warning was officially added, making the lag time between first awareness of a problem and the FDA’s formal warning a central issue in litigation. For instance, if internal company documents show that a manufacturer was aware of serious adverse events but continued marketing the drug without adequate warnings for months or years before the black box warning was added, this evidence can be particularly damaging in court or settlement negotiations. The landscape of black box warning litigation continues to evolve as more medications come under regulatory scrutiny and as plaintiffs’ lawyers become more sophisticated in identifying cases and building claims. The volume of litigation for any particular black box warning drug depends on several factors: how widely the medication was prescribed, how severe the documented injuries are, how long the drug was on the market without a warning, and how active plaintiffs’ law firms are in recruiting clients and filing cases.
How Manufacturers Face Legal Liability for Black Box Warnings
Pharmaceutical manufacturers face liability for black box warning cases under several legal theories, all grounded in the principle that companies have a duty to warn consumers and healthcare providers about known or knowable serious risks. Under product liability law, a medication can be considered defective—and its manufacturer liable for injuries—if the manufacturer failed to provide adequate warnings about serious hazards. When the FDA has added a black box warning to a drug, plaintiffs’ attorneys argue that this FDA determination proves the manufacturer either knew or should have known about the serious risk, and therefore the manufacturer’s failure to warn (before the black box warning was added) or failure to take protective measures (even after the warning was added) constitutes a defect. The legal standard for manufacturer liability typically requires plaintiffs to prove that: (1) the medication caused the injury; (2) the manufacturer knew or should have known about the risk; (3) the manufacturer failed to adequately warn or failed to take sufficient precautions; and (4) the patient suffered damages (medical expenses, lost wages, pain and suffering, etc.). In black box warning cases, elements (1) and (2) are often easier to establish because the FDA has already made a formal finding that the drug poses a serious documented risk.
The defendant manufacturer can argue that it did provide warnings, that the black box warning was eventually added, and that the patient’s injury resulted from other causes. However, these defenses are generally weaker in cases where the FDA’s warning was delayed or where internal evidence suggests the manufacturer knew about dangers but didn’t act quickly enough. A crucial limitation in many black box warning cases is that manufacturers may not be fully liable if they can demonstrate that they warned healthcare providers or that the prescribing physician should have been aware of risks through professional literature or medical journals. This is called the “learned intermediary doctrine,” which holds that manufacturers have fulfilled their duty to warn if they adequately inform physicians, who then serve as intermediaries between the manufacturer and the patient. However, this defense is weaker in cases where the black box warning is added years after the medication was on the market, suggesting that the risks were not well-known to the medical community prior to the FDA’s formal action. Additionally, some states have recognized exceptions to the learned intermediary doctrine for direct-to-consumer marketing, where manufacturers advertise medications directly to patients without adequate safety information.
Recent FDA Changes and Their Impact on Black Box Warning Lawsuits
In November 2025, the FDA made a significant regulatory change by removing the black box warning from hormone replacement therapy (HRT) for menopausal women. This decision reflected a reassessment of the benefit-risk profile of HRT based on newer evidence, clinical guidelines, and changes in prescribing practices. The removal of the black box warning represents an important regulatory shift and may affect future litigation regarding HRT. However, and this is a critical point for patients who were harmed while the black box warning was in effect, prior injuries caused by HRT during the period when it carried a black box warning remain legally actionable. This means that patients who suffered serious adverse events—such as blood clots, stroke, heart attack, or breast cancer—while taking HRT under the black box warning remain eligible to pursue lawsuits against manufacturers. The HRT example illustrates an important principle in black box warning litigation: the timing of the warning matters legally. A manufacturer can face liability for injuries caused during the time the drug carried a black box warning, even if the warning is later removed.
This is because the manufacturer had an opportunity to prevent harm by taking stronger precautions, discouraging inappropriate use, or more aggressively warning about the dangers during the warning period. The removal of the warning suggests that newer data, better understanding of risks, or changes in medical practice have altered the benefit-risk calculation, but it does not erase the fact that harm occurred during the warning period when risks were deemed serious enough to warrant the strongest FDA alert. A significant limitation to understand is that the removal of a black box warning does not automatically trigger new litigation or reopen old claims. Statutes of limitations apply to lawsuits, meaning that patients generally must file claims within a certain timeframe from when they discovered the injury or reasonably should have discovered it. For conditions with long latency periods, such as certain cancers caused by medications, the statute of limitations may be extended or may run from diagnosis rather than exposure. However, for acute injuries or conditions diagnosed shortly after medication use, the statute of limitations may have already expired even if the black box warning is later removed. Anyone who believes they were harmed by a medication that carried a black box warning should consult with an attorney promptly to understand whether they have a viable claim before the statute of limitations expires.
What to Do If You Believe You’ve Been Harmed by a Black Box Warning Medication
If you or a family member has suffered an injury that you believe is connected to a medication that carries or carried a black box warning, several steps can help protect your legal rights. First, gather and preserve medical documentation related to your injury, including medical records from hospitalizations, emergency room visits, psychiatric evaluations, medication lists, and pharmacy records showing what you were prescribed and when. Documentation of the timeline—when you started taking the medication, when symptoms or injuries appeared, and how the condition progressed—is valuable evidence. Additionally, any communications from healthcare providers discussing side effects or risks, or expressing concern about your symptoms, should be preserved as they may support your claim.
Second, consult with an attorney who specializes in pharmaceutical injury or mass tort litigation. Many firms that handle black box warning lawsuits work on a contingency fee basis, meaning they only get paid if you recover compensation through settlement or judgment. An experienced attorney can evaluate your case, determine whether you have a viable claim, advise you on procedural issues such as whether you should join a consolidated litigation or file an individual suit, and help you understand the statute of limitations deadline in your state. For conditions caused by medications like Singulair, where psychiatric injuries are involved, an attorney may work with psychiatric experts to establish the causal link between the medication and your injury. For medications like HRT or others where the injury may be a serious condition such as blood clots or cancer, medical expert testimony connecting the medication to the condition is typically essential to winning or settling a case.
The Future of Black Box Warning Litigation
The landscape of black box warning litigation is likely to continue evolving as pharmaceutical regulatory science advances and as more medications come under legal scrutiny. The FDA’s November 2025 reassessment of HRT demonstrates that regulatory decisions are dynamic and based on the best available evidence at the time. However, manufacturers cannot use future regulatory changes as a shield against liability for harms that occurred during black box warning periods.
Going forward, we can expect continued litigation over medications like Singulair and Suboxone, as well as new litigation as additional black box warnings are added to other medications or as evidence of previously unknown risks emerges. One forward-looking consideration is whether the pharmaceutical industry will become more cautious about bringing medications to market or will implement stronger internal safety monitoring systems to identify serious risks more quickly. If manufacturers identify risks sooner and advocate for black box warnings promptly rather than years after a problem becomes apparent, it may reduce litigation exposure. Conversely, if manufacturers continue to delay acknowledgment of serious risks, black box warning litigation will likely remain a significant category of pharmaceutical injury litigation, protecting patients’ rights to compensation for harm caused by medications with known, documented dangers.
Conclusion
A black box warning lawsuit is a legal claim for injuries caused by a medication that carries the FDA’s strongest safety warning. These lawsuits are among the most serious pharmaceutical injury cases because the FDA has already made a formal finding that the medication poses a known, significant risk. The Singulair neuropsychiatric litigation, with 247 cases consolidated in New Jersey as of March 2022, exemplifies how a black box warning can trigger substantial mass tort litigation affecting thousands of patients. Other medications with active black box warning lawsuits include Suboxone, Ozempic, and many others, and manufacturers face significant legal liability when they fail to adequately warn about or protect against risks that the FDA has determined warrant a black box warning.
If you or a family member has experienced a serious injury related to a medication with a black box warning, it is important to act promptly to protect your legal rights. Consult with an attorney who specializes in pharmaceutical injury litigation, gather documentation of your injury and medication history, and understand the statute of limitations in your state. Black box warning litigation may take months or years to resolve, but many cases result in settlements that compensate patients for medical expenses, lost wages, and pain and suffering. The FDA’s authority to add black box warnings to medications serves to protect public health, and the legal system’s recognition of liability for black box warning injuries ensures that manufacturers face accountability for failing to protect patients from known, serious risks.
Frequently Asked Questions
What is the difference between a black box warning and a standard warning on medication packaging?
A black box warning is the FDA’s strongest safety alert and indicates that a medication has evidence of serious or life-threatening adverse events. Standard warnings are less severe and indicate potential risks that do not rise to the level of serious or life-threatening harm. Black box warnings are visually distinct, with a black box border on the medication label.
Can you sue a pharmaceutical manufacturer if you were injured by a medication with a black box warning?
Yes, you can potentially sue if you can prove that the medication caused your injury and that the manufacturer failed to adequately warn or failed to take sufficient precautions to protect you from the known risk. However, you must act within the statute of limitations, which varies by state and the type of injury.
How long do I have to file a lawsuit for a black box warning medication injury?
The statute of limitations depends on your state and the nature of your injury. Most states allow 2-3 years from the date you discovered the injury, though some allow longer periods for conditions with delayed diagnosis. Consult with an attorney in your state to determine your specific deadline.
Are black box warning lawsuits typically settled or decided at trial?
Most pharmaceutical injury cases, including black box warning cases, result in settlements rather than trials. However, some cases do go to trial, and settlement amounts vary widely depending on the severity of injury, jurisdiction, and strength of evidence.
If the FDA removes a black box warning from a medication, does that affect my lawsuit?
No, if you were injured while the black box warning was in effect, you may still have a valid claim even if the warning is later removed. The manufacturer’s liability is based on its conduct and knowledge during the time the black box warning was required.
How do I know if a medication I took carries or carried a black box warning?
You can check the FDA’s website or your medication’s package insert (information sheet) for black box warnings. You can also consult with a pharmacist or attorney, and search FDA databases for the medication’s history and current labeling.